ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1001

CNstream2: Improved SNP and CNV Genotyping Reveals New Loci Associated with Rheumatic Diseases

Arnald Alonso, Antonio Julià, Raül Tortosa and Sara Marsal, Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Epidemiologic methods, genomics and rheumatic disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Genetics and Genomics of Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose: In Genome-Wide Association Studies (GWAS), the performance of the genotyping algorithm is crucial to identify new SNPs associated to disease risk. Recently, new methods have been developed to exploit SNP-oriented microarrays in order to genotype Copy Number Variations (CNVs), albeit with a reduced performance compared to SNPs. In this study we present CNstream2, a method for both SNP and CNV genotyping that achieves a superior accuracy compared to other established methods. In addition, we have identified several new CNV loci that are in high linkage disequilibrium (LD) with SNPs previously associated to rheumatic diseases.

Methods: CNstream2 is a substantially improved version of our previous CNstream software which achieves a superior accuracy in both SNP and CNV genotyping compared to other well-established methods (i.e. GenoSNP/GenCall for SNP genotyping and PennCNV/QuantiSNP for CNV genotyping). All these improvements have been assessed in different Illumina platforms using public microarray data from HapMap samples. SNP genotypes from the 1000 Genomes Project (1KGP) and CNV genotypes from recent studies using CNV-oriented technologies have been used as golden standards for performance comparisons. In order to show the power of CNstream2, we performed a correlation analysis between SNPs associated with rheumatic diseases reported by the GWAS catalog and the CNVs identified by CNstream2 over the same HapMap samples using HumanOmni1 data. All the CNV loci that obtained an r2>0.7 (N=16) were reported in this study.

Results: CNstream2 obtained a high performance both on SNP and CNV genotyping. When assessing SNP genotyping accuracy, CNstream2 obtained an average gain of 0.20% with respect to GenoSNP and GenCall (representing a gain of 1,000-2000 genotyped SNPs per GWAS). On the other hand, when comparing CNV calls obtained by CNstream2, PennCNV and QuantiSNP within previously characterized CNV loci, CNstream2 exceeded by an average of 20% the number of correctly captured loci compared to its competitors. The LD analysis between SNPs associated to rheumatic diseases and CNVs detected by CNstream2 revealed 16 highly correlated SNP-CNV pairs. From these, 11 pairs were located in the HLA region and were associated to several rheumatic diseases. Given the strong correlation of the CNV with the disease risk SNP, additional functional studies exploring its relevance are warranted. Outside the HLA region, 5 new CNVs from loci associated with rheumatological diseases were identified. From these, a previously unidentified intronic deletion in Rheumatoid Arthritis risk gene PADI4, showed a strong association. 

Conclusion: After an exhaustive evaluation of CNstream2 performance we can conclude that this new software tool provides an unprecedented accuracy both in SNP and CNV genotyping. Using CNStream2 on publicly available data, we have identified new CNVs on loci previously associated to rheumatological diseases which could likely explain the observed disease risk association.


Disclosure:

A. Alonso,
None;

A. Julià,
None;

R. Tortosa,
None;

S. Marsal,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cnstream2-improved-snp-and-cnv-genotyping-reveals-new-loci-associated-with-rheumatic-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology